Skip to content

Trial Summary

The purpose of this study is to determine if APOMAB, (an imaging agent which is an antibody with a small amount of radiation attached to it) which has been designed to detect tumour cell death, is safe and tolerable to use in humans.

Acronym:

APOMAB

ACTRN/NCT /ethics:

Scientific title:

This trial is a phase 1, single-centre, open label, single-dose study of 89Zr-APOMAB using PET/CT imaging in a series of 18 participants who are known to have inoperable stage III or stage IV non-small cell lung cancer (NSCLC), or limited or extensive stage small cell lung cancer (SCLC), or FIGO stage IV grade 3 serous papillary Ovarian Cancer.

Trial & Patient Characteristics

Cancer TypeGynaecological, Lung & Mesothelioma
Trial TypeTreatment
PhasePhase I
Age Range18+ years
SexBoth
Tumour StreamLung or Ovarian Cancer
Cancer StageLocally Recurrent or Locally Advanced; Metastatic or Widespread
Anticipated Start Date2020-06-01
Anticipated End Date2021-12-31

Participating Hospitals

HospitalRoyal Adelaide Hospital
Clinical Trial CoordinatorAnne Milton
Emailanne.milton@sa.gov.au
Phone08 7074 2342
Principal InvestigatorProfessor Michael Brown
Recruitment StatusRecruiting